Provided by Tiger Trade Technology Pte. Ltd.

Tredegar

7.78
-0.1500-1.89%
Post-market: 7.780.00000.00%19:30 EDT
Volume:114.88K
Turnover:891.54K
Market Cap:271.61M
PE:8.13
High:7.92
Open:7.89
Low:7.67
Close:7.93
52wk High:10.53
52wk Low:6.25
Shares:34.91M
Float Shares:28.88M
Volume Ratio:0.62
T/O Rate:0.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.9572
EPS(LYR):0.9604
ROE:15.47%
ROA:6.50%
PB:1.19
PE(LYR):8.10

Loading ...

TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)

GlobeNewswire
·
Jun 03

TG Jones owner Modella puts jobs at risk in shoe retailer overhaul

cityam
·
Jun 02

Bonnell Aluminum names Carl Czarnik senior vice president, general manager

Reuters
·
Jun 02

Tredegar Announces Bonnell Aluminum Leadership Changes

THOMSON REUTERS
·
Jun 02

Tredegar 10% owner William M. Gottwald sells common shares worth $33,672

Reuters
·
Jun 02

Tredegar files Form 3 for Susan E. Sweeney, vice president and chief human resources officer

Reuters
·
Jun 01

Tredegar files Form 3 naming Joseph E. Haniford as director beneficial owner

Reuters
·
Jun 01

TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology

GlobeNewswire
·
Jun 01

TG Metals Advances Lake Johnston Lithium Project with Burmeister Mining Lease Application

TIPRANKS
·
Jun 01

Tredegar 10% owner William M. Gottwald sells shares worth $163,148.35

Reuters
·
May 29

Tredegar 10% owner James T. Gottwald reports sale of 20,496 common shares worth $164,231

Reuters
·
May 29

TG Metals Starts Drilling to Expand Van Uden Laterite Gold Resource

TIPRANKS
·
May 28

Tredegar Announces Board Changes and New Independent Director

TIPRANKS
·
May 28

Tredegar names Joseph Haniford independent director as two board members step down

Reuters
·
May 28

Tredegar Announces Director Transitions

THOMSON REUTERS
·
May 28

TG Therapeutics Price Target Maintained With a $70.00/Share by HC Wainwright & Co.

Dow Jones
·
May 28

TG Therapeutics reports ENHANCE trial meets primary endpoint

TIPRANKS
·
May 27

New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia

GlobeNewswire
·
May 27

TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial

GlobeNewswire
·
May 27

Tredegar names Susan Sweeney as chief human resources officer effective June 1, 2026

Reuters
·
May 27